Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAVENS: Radium-223 and SABR vs SABR for Oligometastatic Prostate Cancer
NCT04037358Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Aug 2019
- Primary completion
- Jul 2025
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
A Phase 2 trial of radium-223 dichloride in prostate cancer (PCa), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Aug 2019; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04037358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04037358.